UNSPSC 51262411: Procaterol hydrochloride

This classification denotes an adrenergic beta-2 receptor agonist C16H22N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4VD1BRT7T8, chemically known as 2(1h)-quinolinone, 8-hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-, monohydrochloride, (r*,s*), (+/-)-, but more generally known as procaterol hydrochloride, which bears US NIH Compound Identifier 43091. European Medicines Agency schedules Procaterol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04050MIG.

Most nations, for tariff and trade purposes, schedule procaterol hydrochloride under HS 29337900 and SITC 51561. As of Q4 2014, PROCATEROL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC[C@H]([C@H](C1CCC(C2C1CCC(=O)[NH]2)O)O)NC(C)C.CL.

UNSPSC 51262411 Procaterol hydrochloride is a Commodity code tracking pharmaceutical products, though recent state and local solicitation activity under this code shows a significant mismatch: the single posted opportunity is Seminole County, Florida's IFB60459723LAS for Naloxone and Safe Drug Deactivation Systems, neither of which corresponds to procaterol hydrochloride, a beta-2 agonist used in respiratory treatment. State and local governments do not appear to be actively procuring procaterol hydrochloride under this code at present.

The Seminole County solicitation—an Invitation for Bid posted June 30, 2026, with response due July 26, 2023—requested 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building in Sanford, Florida, with all shipping included in vendor pricing. The contract carries a two-year initial term plus one-year renewal option, a three-month probationary termination window, and potential FEMA funding with associated federal compliance obligations. No set-aside designations are noted. Given the absence of aligned procurement activity and the single opportunity's focus on opioid-reversal and drug-disposal products unrelated to the code's nominal pharmaceutical scope, this code shows little relevant recent state and local buying activity.